Diabetic macrovascular disease: The glucose paradox?

Circulation

Volumn 106, Issue 22, 2002, Pages 2760-2763

  Libby, Peter ^a   Plutzky, Jorge ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Atherosclerosis; Diabetes mellitus; Editorials; Lipid; Risk factors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANCED GLYCATION END PRODUCT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CELL SURFACE RECEPTOR; ENALAPRIL; FELODIPINE; FENOFIBRATE; GEMFIBROZIL; GLUCOSE; INSULIN; LOSARTAN; METFORMIN; PRAVASTATIN; SIMVASTATIN; SULFONYLUREA DERIVATIVE;

ATHEROMA; CARDIOVASCULAR RISK; DIABETES CONTROL; DYSLIPIDEMIA; EDITORIAL; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR DISEASE;

ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERLIPIDEMIAS; METABOLIC SYNDROME X; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 0037180527     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000037282.92395.AE     Document Type: Editorial

References (15)

1. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286:1195-1200.
2. Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.
3. Vlassara H. Recent progress in advanced glycation end products and diabetic complications. Diabetes. 1997;46:S19-25.
4. Bucciarelli LG, Wendt T, Qu W. Rage blockade stabilizes established atherosclerosis in diabetic apolipoprotein e null mice. Circulation. 2002;106:2827-2835.
5. Libby P. The molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
6. Haffner SM. Epidemiological studies on the effects of hyperglycemia and improvement of glycemic control on macrovascular events in type 2 diabetes. Diabetes Care. 1999;22:C54-56.
7. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
8. Wild SH, Dunn CJ, McKeigue PM, et al. Glycemic control and cardiovascular disease in type 2 diabetes: A review. Diabetes Metab Res Rev. 1999;15:197-204.
9. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA. 2002;287:2570-2581.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-865.
11. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: Possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001;8:203-210.
12. Kern PA, Ranganathan S, Li C, et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280:E745-751.
13. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation. 2001;103:2531-2534.
14. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;23:831-834.
15. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res. 1999;84:1085-1094.